Breakthrough blood test personalizes and optimizes prostate cancer treatment

Date Posted: 
2015-03-24

A breakthrough study published in Clinical Cancer Research describes a minimally invasive method for interrogating mechanisms of therapeutic resistance in metastatic castration-resistant prostate cancer.

Scientists from the Vancouver Prostate Centre lead by Dr. Kim Chi, along with their international collaborators, have performed the largest cohort study of patients with advanced prostate cancer to look for prostate cancer-specific mutations in circulating cell-free DNA (cfDNA) (i.e. from blood samples). It is the first study to tie such results to clinical outcomes.   

VPC researchers are further testing their findings in several clinical trials. If the trials show a strong connection between the genetic profile and treatment, the blood test will hopefully roll out to clinical use.

Read more at the VCHRI news release and at the Clinical Cancer Research publication.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Movember Foundation 2018

Movember 2018

The Movember Foundation's fundraiser runs from November 1 to 30.  Click here to donate to The Vancouver Prostate Centre team as we join teams across Canada to raise funds for men's health research in the areas of prostate cancer, testicular cancer, mental health and suicide prevention.

Employment

Work at the Vancouver Prostate Centre

Tuesday, November 27, 2018

An innovative new study advances personalized medicine for prostate cancer patients

Drs Chi and Wyatt
Tuesday, October 23, 2018

Three researchers receive Prostate Cancer Canada & Movember Foundation grants for biomarker development